ProShare Advisors
OMED

ProShare Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

ProShare Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-21,195
Closed -$96K – 1818
2017
Q3 		$96K Buy
21,195
+1,883
+10% +$7.63K ﹤0.01% 1329
2017
Q2 		$64K Sell
19,312
-2,928
-13% -$12.1K ﹤0.01% 1414
2017
Q1 		$205K Sell
22,240
-5,673
-20% -$49.8K ﹤0.01% 1444
2016
Q4 		$215K Buy
27,913
+2,518
+10% +$23.1K ﹤0.01% 1560
2016
Q3 		$290K Buy
25,395
+700
+3% +$8.15K ﹤0.01% 1166
2016
Q2 		$304K Buy
24,695
+338
+1% +$4.1K ﹤0.01% 1204
2016
Q1 		$246K Sell
24,357
-2,320
-9% -$27.2K ﹤0.01% 1306
2015
Q4 		$601K Buy
26,677
+2,134
+9% +$43.7K 0.01% 957
2015
Q3 		$407K Sell
24,543
-1,576
-6% -$31.6K 0.01% 1003
2015
Q2 		$588K Sell
26,119
-359
-1% -$8.85K 0.01% 1027
2015
Q1 		$683K Buy
26,478
+4,005
+18% +$102K 0.01% 1033
2014
Q4 		$489K Buy
22,473
+2,114
+10% +$43.3K 0.01% 1206
2014
Q3 		$385K Sell
20,359
-3,741
-16% -$75.2K 0.01% 1566
2014
Q2 		$562K Sell
24,100
-3,162
-12% -$78.1K 0.01% 1518
2014
Q1 		$917K Buy
27,262
+14,684
+117% +$495K 0.01% 1378
2013
Q4 		$371K Buy
+12,578
New +$230K 0.01% 1114

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

ProShare Advisors's OMED Position: Q4 2017 in Review

ProShare Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2017, closing a stake of 21,195 shares — an estimated $96K sold.

ProShare Advisors first reported a position in OMED in Q4 2013 and held it in 16 quarters. The position peaked at $917K in Q1 2014. 69 funds tracked by Wall St. Rank hold OMED as of Q4 2017.

  • ProShare Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • ProShare Advisors sold 21,195 OncoMed Pharmaceuticals, Inc. shares in Q4 2017, an estimated $96K.
  • ProShare Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 16 quarters.
  • ProShare Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $917K in Q1 2014.
  • 69 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2017.

Based on ProShare Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.